We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
-4.04%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$317M
AUM Growth
-$74.8M
(-19%)
Cap. Flow
-$34M
Cap. Flow
% of AUM
-10.74%
Top 10 Holdings %
Top 10 Hldgs %
58.38%
Holding
40
New
11
Increased
7
Reduced
13
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$26.2M |
| 2 |
Cigna
CI
|
+$17.8M |
| 3 |
Merck
MRK
|
+$16M |
| 4 |
Pfizer
PFE
|
+$15.8M |
| 5 |
Amgen
AMGN
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$20.3M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$18M |
| 3 |
Abbott
ABT
|
+$17.5M |
| 4 |
AET
Aetna Inc
AET
|
+$17.3M |
| 5 |
CVS Health
CVS
|
+$14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.36% |
| 2 | Financials | 2.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cencora
COR
$60.6B
| $4.97M | 1.57% |
+57,600
| New | +$5.53M |
|
|
CNCE
27
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $4.56M | 1.44% |
199,139
-77,206
| -28% | -$1.72M |
|
28
Theravance Biopharma
TBPH
$874M
| $4.55M | 1.44% |
187,856
+16,056
| +9% | +$441K |
|
|
AERI
29
DELISTED
Aerie Pharmaceuticals
AERI
| $3.83M | 1.21% |
70,668
-207,732
| -75% | -$11.6M |
|
30
AnaptysBio
ANAB
$1.58B
| $2.62M | 0.83% |
+25,200
| New | +$2.84M |
|
31
Protagonist Therapeutics
PTGX
$8.79B
| $1.51M | 0.48% |
175,990
-4,010
| -2% | -$75.5K |
|
|
32
Abbott
ABT
$183B
| – | – |
-307,400
| Closed | -$17.5M |
|
33
Encompass Health
EHC
$11B
| – | – |
-146,189
| Closed | -$5.75M |
|
34
Halozyme
HALO
$9.79B
| – | – |
-537,500
| Closed | -$10.9M |
|
35
Rocket Pharmaceuticals
RCKT
$340M
| – | – |
-159,256
| Closed | -$1.66M |
|
|
SEM
36
DELISTED
Select Medical
SEM
| – | – |
-910,368
| Closed | -$8.66M |
|
|
RVNC
37
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-236,355
| Closed | -$8.45M |
|
|
CERN
38
DELISTED
Cerner Corp
CERN
| – | – |
-169,000
| Closed | -$11.4M |
|
|
FOMX
39
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| – | – |
-377,397
| Closed | -$2.27M |
|
|
AVXS
40
DELISTED
AveXis, Inc. Common Stock
AVXS
| – | – |
-58,100
| Closed | -$6.43M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q1 2018 Portfolio in Review
As of Q1 2018, Senzar Asset Management held 40 positions worth $317M, down 19% from $392M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Senzar Asset Management withdrew a net $34M in Q1 2018, closing 9 positions and reducing 13 holdings. Its most notable exit was Abbott, an estimated $17.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 78% a quarter earlier, followed by Financials.
Against the trend, Senzar Asset Management opened a new position in AstraZeneca worth $26.5M.
- Senzar Asset Management's largest Q1 2018 buy was AstraZeneca: 378,855 shares worth $26.5M.
- Senzar Asset Management added most to Allergan plc in Q1 2018, an estimated $7.29M increase.
- Senzar Asset Management's biggest Q1 2018 reduction was Sanofi, cutting an estimated $20.3M.
- Senzar Asset Management fully exited Abbott in Q1 2018, selling an estimated $17.5M.
- Senzar Asset Management's ten largest holdings make up 58% of its $317M portfolio in Q1 2018.
- Senzar Asset Management opened 11 new positions and closed 9 in Q1 2018.
- Senzar Asset Management's portfolio value fell 19% quarter-over-quarter to $317M.
Based on Senzar Asset Management's 13F filing for Q1 2018, filed 14 May 2018.